The ACTA International Clinical Trials Conference 2019 brings together Australian and International experts in the cutting-edge design and conduct of clinical trials and registry custodianship, healthcare funding, policy and regulation, healthcare service delivery, health information technology, health economics and patient advocacy.
The Conference theme is Better Health Through Best Evidence, providing a platform for national and international stakeholders to share global advances in the development of self-improving healthcare systems.
The program’s topics include:
- Revolutions in clinical trials
- Data access and open access in trials
- Embedding clinical trials in routine practice
- Novel trials designs and conduct
- Maximising the value of clinical registries
- Interface with industry partners
- Improving public awareness
- The vital role of consumer involvement in clinical research
Speakers include Dr Richard Pazdur, Director of the US Food and Drug Administration Oncology Centre of Excellence and Prof Barbara Bierer, Professor of Medicine, Founder and Leader of the Multi-Regional Clinical Trials Centre of Brigham and Women’s Hospital and Harvard Medical School. Mr Simon Denegri, The National Director for Patients, Carers and the Public in Research at the National Institute of Health Research and Professor Neena Modi, Professor of Neonatal Medicine at Imperial College and Founder of the UK National Neonatal Research Database will also be members of ACTA’s stellar Conference line up.
To find out more go to: www.clinicaltrialsconference.com.au
Schedule
Thursday 3 October
Plenary 1
9:35 - A Clinician's View—Prof John Zalcberg OAM
9:45 - Why and how NHMRC supports clinical trials—Prof Anne Kelso AO
10:05 - MRFF perspective—Prof Ian Frazer AC FRS (slides not available)
Plenary 2
11:00 - Efficiency and quality by design—Dr Pamela Tenaerts
11:25 - Embedded adaptive clinical trials: A new standard?—Prof Derek C. Angus
11:30 - Evidence-based medicine for rare diseases – a new paradigm—Dr Richard Pazdur
Concurrent
Cockle Bay Room
13:30 - RCT approval process – international perspective—Dr Pamela Tenaerts
13:55 - ACSQHC clinical trials governance framework – implications for clinical trials in Australia—Dr Robert Herkes (slides not currently available)
14:20 - The strategy for implementation of the ACSQHC clinical trials governance framework—Dr Bernadette Aliprandi-Costa (slides not available)
C3.3 Room
13:30 - A USA perspective on diversity and inclusion—Prof Barbara Bierer
13:55 - Conducting clinical trials in partnership with Aboriginal and Torres Strait Islander communities—Prof David Peiris
14:20 - Clinical research trials achieving equitable health outcomes for Māori—Dr Matire Harwood
C3.4/5 Room
13:30 - How many times should a cluster crossover trial cross over?—Dr Jessica Kasza
13:48 - Modern approaches to handling missing data in clinical trials—Dr Tom Sullivan
14:06 - Aligning the design, conduct, and analysis of clinical trials using the estimand framework—Ms Sabine Braat
14:24 - Estimating treatment effects following adaptive clinical trials—Prof Ian Marschner
Plenary 3
C3.4/5 Room
15:30 - Trial-only item numbers for the MBS?—Prof Paul Glasziou (slides not currently available)
15:55 - Precision medicine and MSAC – the way forward—Prof Robyn Ward AM
16:20 - Value-based health care: A role for clinical trials—Mr Paul McBride (slides not currently available)
Friday 4 October
Plenary 4
09:35 - Industry and academia; Opportunities for greater partnerships—Dr Anna Lavelle (slides not available) 09:45 - MTP Connect – linking biomedical innovation to clinical trials in Australia—Dr Dan Grant (slides not available) 10:00 - New horizons for clinical trials and device registration—Dr John Skerritt (slides not available) |
Concurrent
Cockle Bay Room
11:00 - What roles should consumers have and should any limits apply?—Simon Denegri OBE
11:20 - How to get started and where to look for consumer assistance?—Dr Belinda Kiely and Ms Leslie Gilham
11:35 - Lessons learned from the ANZMUSC experience—Ms Ornella Clavisi (slides not currently available)
11:54 - ACTA ‘Trial of the year Consumer Involvement Award’ winner from the TORPIDO 30/60 trial—Ms Melinda Cruz
C3.3 Room
11:00 - An ABC of embedded trials—Prof Neena Modi
11:18 - Registry-randomised trials: A practical model of embedding—Prof Chris Reid
11:36 - Waiver of consent for comparative effectiveness trials—Prof Meg Jardine
11:54 - Comparative effectiveness research: The SOCRATES proposal—Prof John Simes
12:12 - Should PROMs and PREMs be standard in clinical care and available for clinical trials?—Prof Christobel Saunders AO
C3.4/5 Room
11:00 - Patient and public perspectives in trials—Prof Tom Walley
11:25 - A framework for evaluating research priorities—A/Prof Rachael Morton (slides not currently available)
11:50 - Value of information analysis in prioritising research—Dr Haitham Tuffaha
Free Papers
Cockle Bay Room 1
13:30 - Conducting placebo controlled randomised trials of surgery in Australia—A/Prof Manuela Ferreira (slides not available)
13:45 - Recruiting for large scale clinical trials in Australian general practice—Prof Mark Nelson
14:00 - N-of-1 trials in clinical research: Opportunities and challenges—Dr Suzanne McDonald
14:15 - Linked data for randomised controlled trials: The George Institute for Global Health experience—Dr Carinna Hockham
14:30 - Can we prospectively estimate the economic returns of clinical trials?—Dr Haitham Tuffaha
14:45 - A new approach to the design of basket oncology trials in rare tumours—Prof Gillian Heller (slides not currently available)
Cockle Bay Room 2
13:30 - The IMPROVinG Evidence-based management and outcomes in communityAcquired Pneumonia (IMPROVE-GAP) trial—Ms Melanie Lloyd (slides not currently available)
13:45 - Protocol for ComeBACK: A pragmatic randomised controlled trial of physical activity coaching for adults with mobility limitations—Dr Leanne Hassett (slides not currently available)
14:00 - Lights, camera, action: Producing educational materials for adaptive trial designs—Ms Grace Currie (slides not currently available)
14:15 - The landscape of clinical trial activity on Indigenous health in Australia: A review using clinical trial registry data from 2008-2018—Dr Ge Xu (slides not currently available)
14:30 - Developing a New Zealand specific framework for research prioritisation in maternal and perinatal health—Clara Mossinger (slides not currently available)
14:45 - Process for waiver of consent in prehospital trials: The EXACT study as an example—Ms Natasha Dodge (slides not currently available)
C3.3 Room
13:30 - Bayesian adaptive trial design to accelerate discovery in regional anaesthesia—Dr Robert Gotmaker
13:45 - Recurrent time-to-event models with ordinal outcomes—Prof Val Gebski (slides not currently available)
14:00 - “Scientists rise up against statistical significance”[1] but type I error equal to 0.05 is what a regulatory body wanted from me—Ms Francesca Orsini (slides not currently available)
14:15 - Changes to aspects of ongoing randomised controlled trials with fixed designs—Dr Andrew Martin (slides not currently available)
14:30 - “Anchoring effect” in random effects meta analysis: A cautionary tale—Dr Gian Luca Di Tanna
14:45 - In cluster randomised trials with binary outcomes, plausible values of (i) the intracluster correlation coefficient and (ii) the standard deviation of true cluster prevalences are bounded by the overall prevalence, its complement, and one third—A/Prof Mark Chatfield
C3.4/5 Room
13:30 - The ORVAC trial protocol – a phase IV, double-blind, randomised, Bayesian adaptive, placebo controlled clinical trial of a third scheduled dose of Rotarix rotavirus vaccine in Australian indigenous infants to improve protection against gastroenteritis—Dr Bianca Middleton
13:45 - A novel methodology for optimising endpoints for cystic fibrosis pulmonary exacerbation trials—A/Prof Tom Snelling (slides not currently available)
14:00 - The Molecular Screening and Therapeutics (MoST) program – A framework platform for multiple, parallel, signal-seeking phase II clinical trials of novel targeted therapies for patients with advanced cancer and unmet clinical need—Dr Lucille Sebastian Platinum (slides not currently available)
14:15 - C: A digital treatment registry for nesting clinical trials of strategies to manage hepatitis C in primary care—Ms Jessica Ramsay
14:30 - The Australasian Teletrial model – access to clinical trials closer to home using telehealth—Prof Sabe Sabesan (slides not currently available)
14:45 - Marketing and trial recruitment: an evaluation of promotional strategies from the T4DM diabetes prevention trial—Ms Karen Bracken (slides not currently available)
Plenary 5
15:45 - The UK Model of consumer engagement in clinical trials—Mr Simon Denegri OBE
16:10 - Consumer prioritisation using the James Lind Alliance method—Prof Jonathan C. Craig
16:35 - A consumer viewpoint of what consumer engagement means—Ms Anne McKenzie AM
17:00 - The consumer ACTA and CT:IQ involvement and engagement toolkit—Ms Anne McKenzie AM and Ms Tanya Symons
Saturday 5 October
Plenary 6
09:00 - A journal perspective—Dr Stuart Spencer (slides not available)
09:25 - The bigger picture; From open access to open scholarship—Prof Virginia Barbour
09:50 - An investigator perspective—Prof Barbara Bierer
Concurrent
Cockle Bay Room
13:30 - Management of linkage variables in clinical trials—Dr Felicity Flack
13:55 - Clinical quality registries and registry based trials – data protection issues—Prof John McNeil (slides not currently available)
14:20 - Harnessing digital technologies for clinical trial research—Dr Charmaine Tam
C3.3 Room
11:00 - How to design, conduct, and report trials optimised for value to end-users: The ACTA implementability guide—Prof Steve Webb
11:20 - Promoting impact and implementation: perspective of a funder—Prof Davina Ghersi (slides not available)
11:40 - Working together to promote implementability and impact: The AHRTC perspective—Prof Chris Levi
12:00 - What role can journals play?—Dr Stuart Spencer (slides not available)
C3.4/5 Room
11:00 - Trials in primary care – lessons from ASPREE—Prof Mark Nelson
11:20 - The REINVEST Study: Challenges in the community—Prof Peter Schofield (slides not currently available)
11:40 - Allied health clinical trials – experience from cerebral palsy—Prof Catherine Elliot
12:00 - NIHR models for primary care and mental health research—Prof Tom Walley CBE
Plenary 7
13:30 - Principles of embedding clinical trials in neonatal care—Prof Neena Modi
14:00 - The concept and challenges: An Australian perspective—Prof Nik Zeps
14:20 - Registry-randomised trials as a pathway to embedding—Prof Stephen McDonald (slides not currently available)
Latest Resources
-
-
Webinar recording: APT Virtual Clinic – ACT-GLOBAL Adaptive Platform Trial for Stroke
-
Workshop: How to better develop cross-network collaborations and linkages
-
The processes involved in a Data and Safety Monitoring Board/Committee with special reference to the role of the various statisticians
-
ACTA 2022-2023 Annual Report
-
ACTA Whistleblower Policy
-
HEAT webinar recording: Design of economic evaluations along the development process
-
Workshops and Virtual Clinics on Adaptive Platform Trials
-
Webinar recording: APT Virtual Clinic – the BAT and PASSPORT Trials
-
Exploring greater partnership between Clinical Trial Networks, Clinical Quality Registries and Trial Coordinating Centres with Industry
-
HEAT Webinar Recording-Flexible survival models and why we (might) need them
-
HEAT Webinar Recording- Use of Administrative Data for Measuring Events and Healthcare Use
-
Recommendations to improve cultural and linguistic diversity in clinical trials
-
Adaptive Platform Trial Summaries
-
Approaches to prioritising research
for clinical trial networks: a scoping review -
HEAT Webinar Recording- Economic Evaluation Alongside Adaptive Trials
-
ACTA 2021-2022 Annual Report
-
Effective strategies to manage data integrity risks webinar
-
The Data Lifecycle: Ethical use of data webinar
-
Transparency in data analyses webinar
-
Economic evaluation alongside cluster trial – webinar recording
-
Development of the Consumer Involvement and Engagement Toolkit
-
Activities supporting the growth of Clinical Trial Networks in Australia
-
Strengthening the capacity, efficiency and effectiveness of Clinical Trials Networks: Activity Overview 2017–2021
-
ACTA 2020-2021 Annual Report
-
MEDIA RELEASE: ACTA appoints Prof Steve Webb as its new Chair and Ian Wilson as Additional Independent Director
-
Official Opening of the 2020 ACTA Summit: Minister’s Address
-
ACTA Year in Review: Financial Year 2019-2020
-
Statistical Analysis Plan (SAP)
-
ACTA Board Charter
-
ACTA Constitution
-
Beyond COVID-19: A solution-focussed forum
-
ACTA Trial of the Year Award 2020 guidelines and nomination forms
-
ACTA Year in Review: Financial Year 2018-2019
-
ACTA Resources Brochure
-
ACTA activity work plan 2019 – 2020
Latest Events
-
ACTA 2024 Trial of the Year Awards
-
Webinar: National Clinical Trials Governance Framework: Update from sites that have been through accreditation
-
ACTA 2023 International Clinical Trials Symposium
-
Sector consultations – online discussion with ACTA
-
Economic Evaluation Alongside Adaptive Trials webinar – 22 November
-
2022 ACTA ASM including the Australian Registry ASM
-
Improving clinical trial recruitment through innovative technologies
-
Clinical Quality Registries (CQR) SIG member webinar – Oct 2022
-
ACTA CEO update – October 2022
-
ACTA STInG 3 part webinar series on Data Transparency (DT)
-
ACTA CEO update – August 2022
-
Economic evaluation alongside cluster trial webinar
-
Clinical Trials (CT) Socials
-
Clinical Trials 2022: National Tribute and Awards
-
Clinical Trials 2021: National Tribute and Award Ceremony
-
Clinical Trials 2020: National Tribute and Award Ceremony
-
ACTA Summit and Clinical Trials 2020 National Tribute and Award Ceremony
-
ACTA Annual General Meeting
-
ACTA Advisory Council